Literature DB >> 32242261

Analysis of ocular surface damage and visual impact in patients with primary and secondary Sjögren syndrome.

Antonio J Villarreal-Gonzalez1, I Jocelyn Rivera-Alvarado1, Luis A Rodriguez-Gutierrez1, Alejandro Rodriguez-Garcia2,3.   

Abstract

The objective of this study is to review the ocular surface changes and complications of patients with Sjögren syndrome and assess their visual impact. A retrospective, cross-sectional, observational, and descriptive study of patients with Sjögren syndrome diagnosed according to the American-European Consensus Group criteria was designed. Data including age, gender, the reason for consultation, associated systemic disease, visual acuity, and ocular complications were recorded. Dry eye tests including tear meniscus thickness; tear film break-up time; ocular surface staining (fluorescein and lissamine green); and Schirmer I test were performed. A total of 249 patients, 233 women (93.6%) and 16 men (6.4%) were studied. Meibomian gland dysfunction was found in 46% (n = 229 eyes) patients; shortened tear film break-up time in 44% (n = 220 eyes); decreased tear meniscus in 49% (n = 243 eyes); significant superficial punctate keratopathy in 49% (n = 242 eyes); a mean ocular surface staining score of 5.92 points; and a low score for Schirmer I test (mean = 5.4 mm). Eyes with a 4 + corneal fluorescein score showed the worst BCVA (mean = 0.63 ± 0.66 LogMAR, ≤ 20/80 Snellen eq., 95% CI 0.29-0.97), compared to 1 + to 3 + scores (mean = 0.211 ± 0.37 LogMAR, 20/32 Snellen eq., 95% CI 0.53-1.15). Ten eyes (4.0%) presented central corneal ulceration with a mean visual acuity of 20/500 (96% visual loss). Ocular surface alterations related to severe dry eye and complications from Sjögren syndrome may have a significant impact on visual acuity. Secondary Sjögren syndrome to rheumatoid arthritis had the worse dry eye prognosis, visual outcome, and ocular complications.

Entities:  

Keywords:  Dry eye; Lissamine green; Sjögren syndrome; Superficial punctate keratitis; Tear film

Mesh:

Year:  2020        PMID: 32242261     DOI: 10.1007/s00296-020-04568-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  6 in total

Review 1.  Androgen and meibomian gland dysfunction: from basic molecular biology to clinical applications.

Authors:  Li-Xiang Wang; Ying-Ping Deng
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

2.  Meibomian gland atrophy with duration of Sjogren's syndrome in adult females.

Authors:  Sung Rae Noh; Jae Lim Chung; Jeong Min Lee; Kyoung Yul Seo; Kyungmin Koh
Journal:  Int Ophthalmol       Date:  2021-08-19       Impact factor: 2.031

3.  [Evaluation of ocular surface status and function in primary Sjögren's syndrome with hypothyroidism].

Authors:  H Z Yu; W Z Zeng; W Y Wu; Z Q Yao; Y Feng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

4.  A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel.

Authors:  Alejandro Rodriguez-Garcia; Alejandro Babayan-Sosa; Arturo Ramirez-Miranda; Concepcion Santa Cruz-Valdes; Everardo Hernandez-Quintela; Julio C Hernandez-Camarena; Nallely Ramos-Betancourt; Regina Velasco-Ramos; Raul E Ruiz-Lozano
Journal:  Clin Ophthalmol       Date:  2022-04-28

5.  Early Dry Eye Disease Onset in a NOD.H-2h4 Mouse Model of Sjögren's Syndrome.

Authors:  Lili Li; Kimberly J Jasmer; Jean M Camden; Lucas T Woods; Adam L Martin; Yong Yang; Maria Layton; Michael J Petris; Olga J Baker; Gary A Weisman; Carisa K Petris
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

6.  Dry Eye in Systemic Sclerosis Patients: Novel Methods to Monitor Disease Activity.

Authors:  Caterina Gagliano; Elisa Visalli; Mario Damiano Toro; Roberta Amato; Giovanni Panta; Davide Scollo; Giovanni Scandura; Salvatore Ficili; Giorgio Amato; Alessia Benenati; Roberta Foti; Giulia Malaguarnera; Giuseppe Gagliano; Raffaele Falsaperla; Teresio Avitabile; Rosario Foti
Journal:  Diagnostics (Basel)       Date:  2020-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.